Bio/pharma IPRs by the numbers

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Bio/pharma IPRs by the numbers

Figures discussed at the BIO International Convention reveal that bio/pharma IPRs at the Patent Trial and Appeal Board have a lower institution rate and lower claim-cancellation rate than for all IPRs

According to the USPTO’s latest statistics, there have been 108 PTAB petitions filed in the TC 1600 class covering bio/pharma patents. This is 8.1% of all petitions filed.

At the BIO International Convention, the USPTO’s Jackie Wright Bonilla provided further detail on how the TC 1600 class stacks up to others.

She revealed the TC 1600 class has a 64% institution rate for inter partes review (IPR) petitions. This is lower than the 76% institution rate for all IPRs.

The rate of claims being cancelled by the Board in pharma IPRs is also below the average. The TC 1600 class has had 28 final written decisions. In these, 75.5% of instituted claims were cancelled (309 claims cancelled and 100 claims found patentable) and 71.7% of challenged claims were cancelled.

In comparison, in the 323 final written decisions in all IPRs 82.5% of instituted claims have been cancelled and 75.3% of challenged claims have been cancelled.

In the same session, Sterne Kessler’s Eric Steffe gave an overview of PTAB cases that have been appealed to the Federal Circuit. He said 141 appeals from final IPR/CBM decisions were docketed at the Federal Circuit. Of these, 104 (75%) are by patent owners, 18 (13%) are by petitioners and 19 (12%) are cross appeals by both parties,

Nine percent of the appeals are from the biotech/chemistry area, with 13 appeals. Nine of these are by patent owners and four are by petitioners, which Steffe said is “roughly mirroring other technologies in terms of who is making those appeals”.



more from across site and SHARED ros bottom lb

More from across our site

The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
The firm said major IP developments included advising on a ‘landmark’ deal involving green hydrogen production, as well as two major acquisitions
The appointments follow other recent moves in the European market as firms look to bolster their UPC offerings
Deborah Kirk discusses why IP and technology have become central pillars in transactions and explains why clients need practically minded lawyers
Gift this article